/
Unless the context indicates otherwise, references in this Annual Report to the Company, TriSalus, we, us, our and similar terms refer to TriSalus Life Sciences, Inc. (f/k/a MedTech Acquisition Corp.), a Delaware corporation and its consolidated subsidiaries. Overview We are a growing, oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by i…
The business is unprofitable at the operating level (-59.68% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 53.4% YoY with margins expanding 63.2pp.
Negative free cash flow of -$19M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$45M
▲ +53.4% YoY
Net Income (TTM)
-$27M
▼ -30.6% YoY
Op. Margin
-62.45%
▲ +63.2pp YoY
ROIC
-60.93%
▲ +153.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$20M
▲ +54.0% YoY
Op. Cash Flow (TTM)
-$20M
▲ +55.9% YoY
Net Debt
-$23M
Net Cash Position
Cash & Equiv.
$57M
3Y CAGR: +53.9%
Continue Research